Developing World Bioethics 11 (2):63-74 (2011)
This article examines the relationship between bioethics and the therapeutic standards in HIV prevention research in the developing world, focusing on the closure of the pre-exposure prophylaxis (PrEP) trials in the early 2000s. I situate the PrEP trials in the historical context of the vertical transmission debates of the 1990s, where there was protracted debate over the use of placebos despite the existence of a proven intervention. I then discuss the dramatic improvement in the clinical management of HIV and the treatment access movement, and consider how these contexts have influenced research practice. I argue that as HIV prevention trials oblige researchers to observe the rate at which vulnerable people under their care acquire HIV, there is an obligation to provide antiretroviral treatment to seroconverters and other health care benefits that fall within the scope of researchers' entrustment, both to avoid exploitation and to enact reciprocal justice. I argue against propositions that the obligations to provide specific benefits are vague, fall only upon researchers and sponsors, and create injustices by privileging the few over the many. Finally, I contend that the realisation of a broader standard of care in HIV prevention research broadens the role of research from being a simple tool to produce knowledge to a complex intervention that can play a part in the reduction of health disparities
|Keywords||Pre‐exposure prophylaxis standard of care HIV prevention research developing world researcher obligation bioethics|
|Categories||categorize this paper)|
References found in this work BETA
No references found.
Citations of this work BETA
It’s Time: The Case for PrEP as an Active Comparator in HIV Biomedical Prevention Trials.Bridget Haire - 2015 - Journal of Bioethical Inquiry 12 (2):239-249.
Similar books and articles
Revisiting the Ethics of HIV Prevention Research in Developing Countries.Charles Weijer & Guy LeBlanc - unknown
Post-Trial Access to Antiretrovirals: Who Owes What to Whom?Joseph Millum - 2011 - Bioethics 25 (3):145-154.
Access to Treatment in Hiv Prevention Trials: Perspectives From a South African Community.Nicola Barsdorf, Suzanne Maman, Nancy Kass & Catherine Slack - 2010 - Developing World Bioethics 10 (2):78-87.
Intertwining Biomedical Research and Public Health in HIV Microbicide Research.R. Macklin - 2010 - Public Health Ethics 3 (3):199-209.
How Good Is “Good Enough”? The Case for Varying Standards of Evidence According to Need for New Interventions in HIV Prevention.Bridget Haire, John Kaldor & Christopher Fc Jordens - 2012 - American Journal of Bioethics 12 (6):21-30.
Impact of Donor-Imposed Requirements and Restrictions on Standards of Prevention and Access to Care and Treatment in HIV Prevention Trials.S. Philpott, K. West Slevin, K. Shapiro & L. Heise - 2010 - Public Health Ethics 3 (3):220-228.
The Definition of Adequate Care in Externally Sponsored Clinical Trials: The Terminological Controversy About the Concept “Standard of Care”.Hans-Jörg Ehni - 2006 - Science and Engineering Ethics 12 (1):123-130.
The Balm of Gilead: Is the Provision of Treatment to Those Who Seroconvert in HIV Prevention Trials a Matter of Moral Obligation or Moral Negotiation?Charles Weijer & Guy J. Leblanc - 2006 - Journal of Law, Medicine & Ethics 34 (4):793-808.
Randomised Placebo-Controlled Trials and HIV-Infected Pregnant Women in Developing Countries. Ethical Imperialism or Unethical Exploitation.Paquita De Zulueta - 2001 - Bioethics 15 (4):289–311.
Treatment Needs in Hiv Prevention Trials: Using Beneficence to Clarify Sponsor-Investigator Responsibilities.Melissa Stobie & Catherine Slack - 2010 - Developing World Bioethics 10 (3):150-157.
Manufacturing Mistrust: Issues in the Controversy Regarding Foster Children in the Pediatric Hiv/Aids Clinical Trials.Jacquelyn Slomka - 2009 - Science and Engineering Ethics 15 (4):503-516.
What Makes Placebo-Controlled Trials Unethical?Franklin G. Miller & Howard Brody - 2002 - American Journal of Bioethics 2 (2):3 – 9.
Benefits to Research Subjects in International Trials: Do They Reduce Exploitation or Increase Undue Inducement?Angela Ballantyne - 2008 - Developing World Bioethics 8 (3):178-191.
Added to index2010-12-27
Total downloads18 ( #261,079 of 2,146,876 )
Recent downloads (6 months)1 ( #385,700 of 2,146,876 )
How can I increase my downloads?
There are no threads in this forum
Nothing in this forum yet.